Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: " Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good | Globalization and Health BioMed Central Debate Open Access Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices enhancing an endangered global public good Thomas Alured Faunce Address Medical School and College of Law Australian National University Canberra ACT Thomas A Faunce LlB Hons BMed PhD Senior Lecturer. Project Director Globalisation and Health Centre of Governance of Knowledge and Development Regulatory Institutions Network Australia Email Thomas Alured Faunce - Thomas.Faunce@anu.edu.au Corresponding author Published 28 March 2006 Globalization and Health 2006 2 5 doi 10.1186 1744-8603-2-5 Received 30 September 2005 Accepted 28 March 2006 This article is available from http www.globalizationandhealth.cOm content 2 1 5 2006 Faunce licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Expert evaluations of the safety efficacy and cost-effectiveness of pharmaceutical and medical devices prior to marketing approval or reimbursement listing collectively represent a globally important public good. The scientific processes involved play a major role in protecting the public from product risks such as unintended or adverse events sub-standard production and unnecessary burdens on individual and governmental healthcare budgets. Most States now have an increasing policy interest in this area though institutional arrangements particularly in the area of cost-effectiveness analysis of medical devices are not uniformly advanced and are fragile in the face of opposing multinational industry pressure to recoup investment and maintain profit margins. This paper examines the possibility in this context of States commencing negotiations toward bilateral trade agreement provisions and ultimately